An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes

被引：122

作者：

Shams'ili, S

de Beukelaar, J

Gratama, JW

Hooijkaas, H

van den Bent, M

van't Veer, M

Smitt, PS

机构：

[1] Erasmus MC, Dept Neurol, NL-3015 GD Rotterdam, Netherlands

[2] Erasmus MC, Dept Neurosurg, NL-3015 GD Rotterdam, Netherlands

[3] Dept Med Oncol, Lab Clin & Tumor Immunol, Rotterdam, Netherlands

[4] Erasmus MC, Dept Immunol, NL-3015 GD Rotterdam, Netherlands

[5] Erasmus MC, Dept Hematol, NL-3015 GD Rotterdam, Netherlands

来源：

JOURNAL OF NEUROLOGY | 2006年 / 253卷 / 01期

关键词：

paraneoplastic neurological syndromes; anti-Hu; anti-Yo; rituximab;

D O I：

10.1007/s00415-005-0882-0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m(2)). In this uncontrolled, unblinded trial of rituximab, three patients improved >= 1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.

引用

页码：16 / 20

页数：5

共 23 条

[1]

Albert ML, 2000, ANN NEUROL, V47, P9

[2]

Benyahia B, 1999, ANN NEUROL, V45, P162, DOI 10.1002/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO

[3]

2-R

[4] Paraneoplastic syndromes involving the nervous system [J].